January 17, 2025

CDC Urges 24-Hour Bird Flu Tests

The CDC emphasizes timely testing for avian influenza A in hospitalized patients to prevent delays and enhance rapid public health responses. Low person-to-person transmission risk has been reported with ongoing U.S. cases among farmworkers.

Reuters

January 16, 2025

Study: Baloxavir Shows Promise in Nonsevere Influenza

Baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza," finds comprehensive network meta-analysis of 73 trials involving 34,332 participants.

Conexiant

January 16, 2025

FDA Clears First Nicotine Pouches for U.S. Market

FDA grants first-ever marketing authorization for ZYN nicotine pouches following a scientific review that showed lower health risks compared to traditional tobacco products and minimal youth usage.

Conexiant

January 16, 2025

FDA Clears Phase 2 Trial: Lorundrostat for OSA-Hypertension

Mineralys Therapeutics receives FDA clearance for a phase II clinical trial investigating lorundrostat, an aldosterone synthase inhibitor, in patients with moderate-to-severe obstructive sleep apnea and hypertension.

Conexiant

January 15, 2025

FDA to Revoke Red No. 3

Red No. 3 is found in many popular food items, including Pop Tarts, Dole Fruit Packs, Double Bubble Gum, Peeps, and more.

Conexiant

January 15, 2025

Lung Cancer's Paradox: Never-Smokers Outlive Smokers?

New research challenges conventional wisdom as never-smokers with NSCLC present with more advanced disease but achieve median survival of 6.6 years versus 3.9 years in smokers, upending traditional prognostic assumptions.

Conexiant

January 15, 2025

Experimental Antiviral May Shorten Flu Symptoms

Single-dose suraxavir marboxil shortened influenza symptoms, cutting recovery time by 21 hours compared to placebo.

Conexiant

January 15, 2025

Trial Ends Early Over Safety Concern

Keros Therapeutics halts testing of experimental blood pressure treatment due to safety concerns during mid-stage trial, citing excess fluid build up around the heart in patients with pulmonary arterial hypertension.

Reuters

January 15, 2025

PRKG2: Genetic Link Between SSc and LUAD

PRKG2 expression reveals genetic ties between systemic sclerosis and lung adenocarcinoma.

Conexiant